Peptides Similar to PE-22-28
Compare PE-22-28 with related peptides and alternatives
📌TL;DR
- •3 similar peptides identified
- •Semax: Moderate - Both are neuropeptides with cognitive and mood-related research applications
- •Selank: Moderate - Both are short peptides studied for mood and anxiety modulation
Quick Comparison
| Peptide | Similarity | Key Differences |
|---|---|---|
| PE-22-28 (current) | - | - |
| Semax | Moderate - Both are neuropeptides with cognitive and mood-related research applications | PE-22-28 blocks TREK-1 potassium channels for antidepressant effects, while semax modulates BDNF and neurotransmitter pathways as an ACTH analog. Semax is approved in Russia. |
| Selank | Moderate - Both are short peptides studied for mood and anxiety modulation | PE-22-28 targets TREK-1 channels while selank is a tuftsin analog modulating GABAergic and immune pathways. Selank has anxiolytic focus while PE-22-28 targets depression. |
| Pinealon | Low-Moderate - Both are short neuroprotective peptides with limited clinical evidence | PE-22-28 is a TREK-1 blocker with clear antidepressant effects, while pinealon is a tripeptide that modulates gene expression in brain tissue with less defined mechanisms. |
SemaxModerate - Both are neuropeptides with cognitive and mood-related research applications
Differences
PE-22-28 blocks TREK-1 potassium channels for antidepressant effects, while semax modulates BDNF and neurotransmitter pathways as an ACTH analog. Semax is approved in Russia.
Advantages
Clinical approval in Russia, decades of use, well-characterized nootropic and neuroprotective effects, intranasal delivery
Disadvantages
Different mechanism (not ion channel-based), no direct TREK-1 data, less specific target
SelankModerate - Both are short peptides studied for mood and anxiety modulation
Differences
PE-22-28 targets TREK-1 channels while selank is a tuftsin analog modulating GABAergic and immune pathways. Selank has anxiolytic focus while PE-22-28 targets depression.
Advantages
Clinical approval in Russia, anxiolytic properties, immune modulation, established safety profile
Disadvantages
Different mechanism, primarily anxiolytic rather than antidepressant, less potent neurogenesis effect
PinealonLow-Moderate - Both are short neuroprotective peptides with limited clinical evidence
Differences
PE-22-28 is a TREK-1 blocker with clear antidepressant effects, while pinealon is a tripeptide that modulates gene expression in brain tissue with less defined mechanisms.
Advantages
Very small size (tripeptide), oral bioavailability potential
Disadvantages
Much less defined mechanism, no specific ion channel target, weaker evidence base
Peptides Related to PE-22-28#
PE-22-28 is unique among neuropeptides in its specific targeting of TREK-1 two-pore domain potassium channels. Most neuropeptides exert their effects through G protein-coupled receptors or neurotrophic signaling rather than direct ion channel modulation. The following comparisons examine peptides with overlapping research applications in mood and cognition.
Semax#
Semax is an ACTH(4-10) analog approved in Russia for cognitive enhancement and stroke recovery. While both peptides have neuroprotective and cognitive applications, their mechanisms are entirely different. Semax modulates BDNF expression and monoaminergic transmission, whereas PE-22-28 specifically blocks TREK-1 potassium channels. Semax has the advantage of clinical approval and decades of use.
Selank#
Selank is a tuftsin analog approved in Russia for anxiety disorders. Both are short peptides targeting mood-related pathways, but selank primarily modulates GABAergic signaling for anxiolytic effects while PE-22-28 blocks potassium channels for antidepressant effects. The distinction between anxiety and depression targets is relevant for potential applications.
Pinealon#
Pinealon is a synthetic tripeptide with neuroprotective properties in preclinical studies. Both have limited clinical evidence, but PE-22-28 has a clearly defined molecular target (TREK-1) and mechanism, while pinealon's mechanism remains poorly characterized.
Summary Comparison#
| Feature | PE-22-28 | Semax | Selank | Pinealon |
|---|---|---|---|---|
| Mechanism | TREK-1 channel blockade | BDNF / neurotransmitter | Tuftsin / GABA | Gene expression |
| Primary application | Antidepressant | Nootropic | Anxiolytic | Neuroprotection |
| Clinical status | Preclinical | Approved (Russia) | Approved (Russia) | Preclinical |
| Size | 7 amino acids | 7 amino acids | 7 amino acids | 3 amino acids |
| Key advantage | Defined ion channel target | Clinical approval | Anxiolytic approval | Oral bioavailability |
Comparison Context#
PE-22-28 belongs to the Neuropeptide category of research peptides. Comparing PE-22-28 with related compounds helps researchers understand its relative positioning in the therapeutic landscape. Each compound has distinct advantages and limitations that should be considered based on the specific research question or clinical need.
Detailed Comparisons#
The following peptides and compounds are most closely related to PE-22-28 in mechanism, indication, or therapeutic category:
PE-22-28 vs Semax#
Similarity: Moderate - Both are neuropeptides with cognitive and mood-related research applications
Key Differences: PE-22-28 blocks TREK-1 potassium channels for antidepressant effects, while semax modulates BDNF and neurotransmitter pathways as an ACTH analog. Semax is approved in Russia.
Advantages of Semax: Clinical approval in Russia, decades of use, well-characterized nootropic and neuroprotective effects, intranasal delivery
Disadvantages of Semax: Different mechanism (not ion channel-based), no direct TREK-1 data, less specific target
Researchers choosing between PE-22-28 and Semax should consider the development stage, available evidence, and specific research objectives when making their selection.
PE-22-28 vs Selank#
Similarity: Moderate - Both are short peptides studied for mood and anxiety modulation
Key Differences: PE-22-28 targets TREK-1 channels while selank is a tuftsin analog modulating GABAergic and immune pathways. Selank has anxiolytic focus while PE-22-28 targets depression.
Advantages of Selank: Clinical approval in Russia, anxiolytic properties, immune modulation, established safety profile
Disadvantages of Selank: Different mechanism, primarily anxiolytic rather than antidepressant, less potent neurogenesis effect
Researchers choosing between PE-22-28 and Selank should consider the development stage, available evidence, and specific research objectives when making their selection.
PE-22-28 vs Pinealon#
Similarity: Low-Moderate - Both are short neuroprotective peptides with limited clinical evidence
Key Differences: PE-22-28 is a TREK-1 blocker with clear antidepressant effects, while pinealon is a tripeptide that modulates gene expression in brain tissue with less defined mechanisms.
Advantages of Pinealon: Very small size (tripeptide), oral bioavailability potential
Disadvantages of Pinealon: Much less defined mechanism, no specific ion channel target, weaker evidence base
Researchers choosing between PE-22-28 and Pinealon should consider the development stage, available evidence, and specific research objectives when making their selection.
Related Reading#
Frequently Asked Questions About PE-22-28
Explore Further
Disclaimer: For educational purposes only. Not medical advice. Read full disclaimer